Monte Rosa Therapeutics (GLUE) Return on Equity: 2023-2025
Historic Return on Equity for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to 0.08%.
- Monte Rosa Therapeutics' Return on Equity rose 64.00% to 0.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.08%, marking a year-over-year increase of 64.00%. This contributed to the annual value of -0.36% for FY2024, which is N/A change from last year.
- As of Q3 2025, Monte Rosa Therapeutics' Return on Equity stood at 0.08%, which was down 8.40% from 0.09% recorded in Q2 2025.
- Monte Rosa Therapeutics' 5-year Return on Equity high stood at 0.09% for Q2 2025, and its period low was -0.82% during Q1 2024.
- In the last 3 years, Monte Rosa Therapeutics' Return on Equity had a median value of -0.45% in 2024 and averaged -0.37%.
- Data for Monte Rosa Therapeutics' Return on Equity shows a peak YoY spiked of 84bps (in 2025) over the last 5 years.
- Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Return on Equity stood at -0.74% in 2023, then surged by 40bps to -0.34% in 2024, then spiked by 64bps to 0.08% in 2025.
- Its Return on Equity was 0.08% in Q3 2025, compared to 0.09% in Q2 2025 and 0.02% in Q1 2025.